Estrella Immunopharma, Inc.
NASDAQ: ESLA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Cheng Liu
- Employees
- 3
- Headquarters
- EmeryVille, United States
- IPO year
- 2021
- Market cap
- $42.2M
- Website
- https://www.estrellabio.com
Loading ESLA…
Loading profile data…Frequently asked questions about ESLA
What does Estrella Immunopharma, Inc. (ESLA) do?
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and E...
Where does ESLA trade?
Estrella Immunopharma, Inc. (ESLA) trades on the NASDAQ Capital Market.
What sector is ESLA in?
Estrella Immunopharma, Inc. (ESLA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Estrella Immunopharma, Inc.?
Cheng Liu is the chief executive officer of Estrella Immunopharma, Inc. (ESLA).
Where is Estrella Immunopharma, Inc. headquartered?
Estrella Immunopharma, Inc. is headquartered in United States.
Does ESLA pay a dividend?
Estrella Immunopharma, Inc. (ESLA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ESLA go public?
Estrella Immunopharma, Inc. (ESLA) completed its initial public offering in 2021.